<SEC-DOCUMENT>0001477932-23-001328.txt : 20230306
<SEC-HEADER>0001477932-23-001328.hdr.sgml : 20230306
<ACCEPTANCE-DATETIME>20230306160540
ACCESSION NUMBER:		0001477932-23-001328
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230228
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230306
DATE AS OF CHANGE:		20230306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cosmos Health Inc.
		CENTRAL INDEX KEY:			0001474167
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				270611758
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41308
		FILM NUMBER:		23708922

	BUSINESS ADDRESS:	
		STREET 1:		141 W. JACKSON BLVD
		STREET 2:		SUITE 4236
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60604
		BUSINESS PHONE:		312-536-3102

	MAIL ADDRESS:	
		STREET 1:		141 W. JACKSON BLVD
		STREET 2:		SUITE 4236
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60604

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cosmos Holdings Inc.
		DATE OF NAME CHANGE:	20140106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIME ESTATES & DEVELOPMENTS INC
		DATE OF NAME CHANGE:	20091008
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cosm_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cosm="http://cosm.com/20230228"><head><title>cosm_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2023-02-28to2023-02-28">0001474167</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2023-02-28to2023-02-28" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='cosm-20230228.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2023-02-28to2023-02-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:DocumentType">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported)&#160;<strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">February 28, 2023</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:100%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityRegistrantName">Cosmos Health Inc.</ix:nonNumeric> </span></strong></p></td></tr><tr style="height:15px"><td style="width:100%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityFileNumber">000-54436</ix:nonNumeric>&#160;</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityTaxIdentificationNumber">27-0611758</ix:nonNumeric>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of incorporation)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Commission</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">File Number)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityAddressAddressLine1">141 West Jackson Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityAddressAddressLine2">Suite 4236</ix:nonNumeric>,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityAddressCityOrTown">Chicago</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Illinois</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityAddressPostalZipCode">60604</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number, including area code&#160;<strong><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:CityAreaCode">312</ix:nonNumeric>) <ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:LocalPhoneNumber">865-0026</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">Cosmos Holdings Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Symbol</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of Each Exchange</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>On Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:Security12bTitle">Common Stock, $.001 par value</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:TradingSymbol">COSM</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b of this chapter).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company <ix:nonNumeric contextRef="From2023-02-28to2023-02-28" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 28, 2023, Cosmos Health Inc. (the &#8220;Company&#8221;) was issued a five-year secured promissory note (the &#8220;Note&#8221;) in the principal amount of 4,100,000.00 EUR&#160;by Cana Laboratories Holdings (Cyprus) Limited, a corporation organized under the laws of the Republic of Cyprus (&#8220;Cana Holdings&#8221;). The Note bears interest at 5% plus 1 month LIBOR per annum and will be used by Cana Holdings to cover specified obligations. Cana Holdings and its wholly-owned subsidiary, Pharmaceutical Laboratories Cana S.A., a corporation organized under the laws of Greece (&#8220;Cana Pharmaceutical&#8221;) are prohibited from using the proceeds of the Note for any capitalization or debt repayment without the Company&#8217;s prior written consent. The principal amount and all accrued interest and other fees are due upon maturity and may not be prepaid in whole or in part, except as provided therein. The Note is a senior secured obligation of Cana Holdings with first priority on all current and future indebtedness of Cana Holdings and its subsidiaries. A breach or default under any other financial instrument by Cana Holdings or Cana Pharmaceutical that results in a Material Adverse Effect shall, at the Company&#8217;s option, be declared a default under this Note.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Note is secured by: (a) a share pledge agreement of same date over all of the issued and outstanding shares of Cana Pharmaceutical held by Cana Holdings; and (b) a share pledge agreement of same date over all of the issued and outstanding shares of Cana Holdings held by the two shareholders of Cana Holdings, Konstantinos-Gaston Kanaroglou and Konstantina-Mathilde Kanaroglou (the &#8220;Cana Shareholders&#8221;).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Issuance of the Note and the two share pledges completes the first of two transactions contemplated by the Binding Letter of Intent concluded by the Company, Cana Holdings, Cana Pharmaceutical and the Cana Shareholders, dated July 19, 2022, and amended on January 10, 2023 (the &#8220;LOI&#8221;). The second transaction contemplated by the LOI is the acquisition of all of the outstanding shares of Cana Holdings by the Company pursuant to a stock purchase agreement to be concluded no later than March 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The information set for under Item 1.01 above is incorporated by reference herein.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-2-</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(d)&#160;Exhibits&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160; &#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Number</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex101.htm">10.1</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex101.htm">Secured Promissory Note dated February 28, 2023 issued&#160;by Cana Laboratories Holdings (Cyprus) Limited.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex102.htm">10.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex102.htm">Cana Holdings Share Pledge Agreement dated as of February 28, 2023.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex103.htm">10.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex103.htm">Cana Pharmaceutical Share Pledge Agreement dated as of February 28, 2023.</a></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-3-</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>COSMOS HEALTH INC.</strong></p></td><td></td></tr><tr style="height:15px"><td style="width:50%;"></td><td style="width:3%;"></td><td style="width:35%;"></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: March 6, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Georgios Terzis</em></p></td><td></td></tr><tr style="height:15px"><td></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Georgios Terzis</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-4-</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cosm_ex101.htm
<DESCRIPTION>SECURED PROMISSORY NOTE
<TEXT>
<html><head><title>cosm_ex101.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>SECURED PROMISSORY NOTE</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:45%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;Principal Amount:<strong> &#8364; 4,100,000.00</strong></p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:45%;"> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">&nbsp;<strong>&nbsp;</strong>Issue Date:<strong> February 28, 2023 </strong></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For value received, <strong>Cana Laboratories Holding (Cyprus) Limited</strong>, a corporation organized under the laws of the Republic of Cyprus (the &#8220;<strong>Borrower</strong>&#8221;), hereby promises to pay to the order of <strong>Cosmos Health, Inc.</strong>, a corporation organized under the laws of the state of Nevada (the &#8220;<strong>Holder</strong>&#8221;) the principal sum of <strong>Four Million One Hundred Thousand Euros (&#8364;</strong><strong>4,100,000.00</strong> ) (the &#8220;<strong>Principal Amount</strong>&#8221;), together with interest on the Principal Amount on the Maturity Date as set forth below (as may be amended, extended, renewed and refinanced, collectively, this &#8220;<strong>Note</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Principal Amount under this Note shall be disbursed to the Borrower subject to the Borrower having provided confirmation to the satisfaction of the Holder that Borrower has acquired 100% of the outstanding (namely 763.516) common shares of <strong>Pharmaceutical Laboratories Cana S.A</strong>., a company organized under the laws of Greece (the &#8220;<strong>Company</strong>&#8221;) from the prior owners of the Company. The Company hereby agrees to undertake certain covenants and obligations as set out in this Note, and agrees to be bound as a party under this Note solely in respect of such covenants and obligations as stated herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Subject to the previous paragraph the Principal Amount under this Note shall be disbursed to the Borrower 5 working days after the Issue Date. Disbursement shall be by wire transfer to the Borrower&#8217;s bank account as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Bank:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">IBAN:&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;[<strong>INTENTIONALLY LEFT BLANK</strong>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">SWIFT:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Alternative Bank Details:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Name:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Bank:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strong>INTENTIONALLY LEFT BLANK</strong>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">IBAN:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">SWIFT:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Interest on this Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (the <strong>&#8220;Interest Rate&#8221;</strong>). In no event shall the Interest Rate exceed the maximum rate allowed by law; any interest payment which would for any reason be unlawful under applicable law shall not be applied to the Principal Amount. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The maturity date (&#8220;<strong>Maturity Date</strong>&#8221;) of this Note shall be five (5) years from the Issue Date noted above (the &#8220;<strong>Note Term</strong>&#8221;). The Principal Amount, as well as all accrued interest and other fees shall be due and payable on the Maturity Date. Subject to <u>Section 4.8</u> below, this Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any amount of Principal Amount, interest or other amounts due hereunder, which is not paid by the Maturity Date shall bear interest at the lesser of the rate of 7,5% per annum or the maximum legal amount permitted by law (&#8220;<strong>Default Interest Rate</strong>&#8221;), from the due date thereof until the same is paid in full, including following the entry of a judgment in favor of Holder (&#8220;<strong>Default Interest</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="text-align:center;margin:0px">-1-</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All payments due hereunder shall be paid by automatic debit, wire transfer, check or in coin or currency which, at the time or times of payment, is the legal tender for public and private debts in the United States of America and shall be made at such place as Holder or the legal holder or holders of the Note may from time to time appoint in a payment invoice or otherwise in writing and, in the absence of such appointment, then at the offices of Holder at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note. Unless otherwise agreed or required by applicable law, payments will be applied first to any accrued unpaid interest, then to any late charges, and then to the Principal Amount. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a business day, the same shall instead be due on the next succeeding day which is a business day and, in the case of any interest payment date which is not the date on which this Note is paid in full, interest shall continue to accrue during such extension. As used in this Note, the term &#8220;<strong>business day</strong>&#8221; shall mean any day other than a Saturday, Sunday or a day on which commercial banks in the State of Nevada and Cyprus are authorized or required by law or executive order to remain closed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">It is further acknowledged and agreed that the Principal Amount owed by Borrower under this Note shall be increased by the amount of all reasonable expenses incurred by the Holder in connection with the collection of amounts due, or enforcement of any terms pursuant to, this Note. All such expenses shall be deemed added to the Principal Amount hereunder to the extent such expenses are paid or incurred by the Holder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This Note shall be a senior secured obligation of the Borrower, with first priority over all current and future Indebtedness (as defined below) of the Borrower and any subsidiaries (including the Company), whether such subsidiaries exist on the Issue Date or are created or acquired thereafter (each a &#8220;<strong>Subsidiary</strong>&#8221; and collectively, the &#8220;<strong>Subsidiaries</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The obligations of the Borrower under this Note are secured in favor of the Holder pursuant to the terms of: (a) a share pledge agreement, of even date herewith (the &#8220;<strong>Cana Holdings</strong> <strong>Share Pledge Agreement</strong>&#8221;), over all of the issued and outstanding shares of the Borrower by and among the Holder and the Borrower&#8217;s owners (the &#8220;<strong>Borrower Owners</strong>&#8221;) and (b) a share pledge agreement, of even date over all of the issued and outstanding common shares of the Company (the &#8220;<strong>Cana Pharmaceutical Share Pledge Agreement</strong>&#8221; and, together with the Cana Holdings Share Pledge Agreement, the &#8220;<strong>Pledge Agreements</strong>&#8221;), with the terms of both Pledge Agreements attached hereto as <u>Exhibit A</u> and <u>Exhibit B</u>, and made part of this Note. With respect to any Subsidiary created or acquired subsequent to the Issue Date, Borrower agrees to cause such Subsidiary to execute any documents or agreements that would bind the Subsidiary to the terms herein and in the Pledge Agreements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As an inducement for the provision of the Principal Amount under this Note, the Company agrees to be bound by certain provisions and covenants of the Share Pledge Agreements as stated therein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of Borrower and will not impose personal liability upon the Holder thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to the terms above, the following terms shall also apply to this Note:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-2-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ARTICLE I. REPRESENTATIONS AND WARRANTIES OF BORROWER</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Borrower and Company jointly and severally represent and warrant to the Holder that the following statements are true and correct on Issue Date and as of the Maturity Date:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1.1 <u>Organization; Authority; No Conflicts or Consents</u>. Borrower is a corporation duly incorporated, existing and in good standing under the laws of the Republic of Cyprus. Company is a corporation duly incorporated, existing and in good standing under the laws of Greece. The execution, delivery, and performance of this Note and the Pledge Agreements to which Borrower or Borrower Owners (as the case may be) and Company are parties have been duly authorized by Borrower and/or each of the Borrower Owners and the Company and (a) do not and will not violate, conflict with or result in breach of any organizational documents or other contract or agreement of Borrower or Borrower Owners or the Company or (b) require any consent, approval or authorization of, or filing of any certificate, notice, application, report or other document with, any governmental authority or other person except as may be required under applicable law to record or register the priority of any security created under the Pledge Agreements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1.2 <u>Enforceability of Note</u>. This Note has been duly executed and delivered by Borrower and Company, enforceable against Borrower and Company in accordance with its terms.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1.3 <u>Enforceability of Pledge Agreements</u>. The Pledge Agreements, in form as <u>Exhibit A</u> and <u>Exhibit B</u> attached hereto, are valid and enforceable under the laws of the Republic of Cyprus and of the laws of Greece (as the case may be) and, when registered, filed or recorded with the appropriate agency and/or pledge registry of the Republic of Cyprus and of Greece (as the case may be) shall constitute first priority and senior liens and encumbrances over all of the collateral pledged thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1.4 <u>Title to Collateral</u>. The Borrower and the Borrower Owners, as the case may be, are sole and exclusive legal and equitable owners of all rights, title and interest in, and have good, valid and marketable title to, all assets, properties and rights pledged under the Pledge Agreements, free of any liens, claims, interests third party rights, rights of set off, restrictions on use, pledges or other restrictions or encumbrances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1.5 <u>Ranking and Security</u>. So long as the Borrower shall hold any obligation under this Note, its obligations hereunder shall rank senior to any other indebtedness, and securities created under the Pledge Agreements shall rank senior to any other rights, liens, encumbrances or other obligations of the Borrower and the Borrower Owners as the case may be.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ARTICLE II. CERTAIN COVENANTS AND POST CLOSING OBLIGATIONS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">2.1 <u>Restrictions on New Shares</u>. So long as the Borrower shall have any obligation under this Note, the Borrower and the Company shall not without the Holder&#8217;s written consent issue any new shares, convertible notes or bonds or any other securities or enter into any transaction that would result in the issuance of any new shares, convertible notes or bonds or any other securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">2.2 <u>Restrictions on Certain Transactions</u>. So long as the Borrower shall have any obligation under this Note and unless approved in writing by the Holder (which such approval not to be unreasonably withheld), the Borrower and the Company shall not directly or indirectly: (a) change the nature of its business or the Company&#8217;s business; (b) sell, divest, change the structure of any material assets of the Borrower, the Company or any Subsidiary other than in the ordinary course of business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">2.3 <u>Use of Proceeds</u>. [Intentionally left blank]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-3-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ARTICLE III. EVENTS OF DEFAULT</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">3.1 <u>Events of Default</u>. It shall be considered an event of default hereunder if any of the following events listed in this Article III (each, an &#8220;<strong>Event of Default</strong>&#8221;) shall occur:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.1 <u>Failure to Pay Principal Amount or Interest</u>. The Borrower fails to pay the Principal Amount hereof or interest thereon when due on this Note, whether at Maturity, upon acceleration or otherwise. A three (3) day cure period shall apply for failure to make a payment when due.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.2 <u>Breach of Covenants</u>. Borrower, Company or the Borrower&#8217;s Owners, as the case may be, breaches any material covenant, post-closing obligation or other material term or condition contained in this Note or in the Pledge Agreements, and breach continues for a period of ten (10) days.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.3 <u>Breach of Representations and Warranties</u>. Any representation or warranty of the Borrower or Company made herein or in any agreement, statement or certificate given pursuant hereto or in connection herewith, shall be false or misleading in any material respect when made and the breach of which has an effect on the rights of the Holder with respect to this Note and the Pledge Agreements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.4 <u>Receiver or Trustee</u>. Borrower, Company or any subsidiary of Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.5 <u>Judgments or Settlements</u>. (i) Any money judgment, writ or similar process shall be entered or filed against Borrower, Company or any Subsidiary of Borrower or any of its property or other assets for more than $25,000, and shall remain unvacated, unbonded or unstayed for a period of thirty (30) days unless otherwise consented to by the Holder; or (ii) the settlement of any claim or litigation, creating an obligation on the Borrower or Company in amount over $50,000.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.6 <u>Bankruptcy</u>. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against Borrower, Company or any subsidiary of Borrower. With respect to any such proceedings that are involuntary, Borrower and Company shall have a 45 day cure period in which to have such involuntary proceedings dismissed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.7 <u>Change of Control</u>. Any Change of Control of the Borrower or Company, or the dissolution, liquidation, or winding up of Borrower or Company or any substantial portion of their respective business. As used herein, a &#8220;<strong>Change of Control</strong>&#8221; shall be deemed to occur upon the consummation of any of the following events: (a) any person or persons other than Borrower&#8217;s Owners shall beneficially own, directly or indirectly, at least 50% of the total voting power of all classes of capital stock of the Borrower entitled to vote generally in the election of its board; (b) any person or persons other than Borrower shall beneficially own, directly or indirectly, at least 50% of the total voting power of all classes of capital stock of the Company entitled to vote generally in the election of its Board; (c) the sale or other disposition (in one transaction or a series of transactions) of all or substantially all of the assets of the Borrower or Company pursuant to an agreement (or agreements) which has (have) been approved by the shareholders of the Borrower or of the Company except any sale to Holder; or (d) the appointment of a new chief executive officer or board of the Borrower or Company not agreed in writing with Holder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-4-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.8 <u>Cessation of Operations</u>. Any cessation of operations by the Borrower or Company, or the Borrower or Company admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower&#8217;s or Company&#8217;s ability to continue as a &#8220;going concern&#8221; shall not be an admission that the Borrower or Company cannot pay its debts as they become due.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.9 <u>Maintenance of Assets</u>. The failure by Borrower or Company to maintain any intellectual property rights, personal, real property or other assets which are necessary to conduct its business (whether now or in the future), to the extent that such failure would result in a material adverse condition or material adverse change in or affecting the business operations, properties or financial condition of Borrower, the Company or any of its subsidiaries (a &#8220;<strong>Material Adverse Effect</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.10 <u>Failure to Execute Pledge Agreements</u>. The failure of the Borrower, Company or the Borrower&#8217;s Owners (as the case may be) to execute any of the Pledge Agreements or any necessary or appropriate amendments to same as required by the Holder or applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.11 <u>Illegality</u>. Any court of competent jurisdiction issues an order declaring this Note, any of the Pledge Agreements or any provision hereunder or thereunder to be illegal, as long as such declaration was not the result of an act of negligence by the Holder, exclusive of the execution of the Pledge Agreements or the transactions and acts contemplated herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.12 <u>Cross-Default</u>. Notwithstanding anything to the contrary contained in this Note or the Pledge Agreements, a breach or default by the Borrower or Company of any covenant or other term or condition contained in any other financial instrument (the &#8220;<strong>Other Agreement</strong>&#8221;), after the passage of all applicable notice and cure or grace periods, that results in a Material Adverse Effect shall, at the option of the Holder, be considered a default under this Note, in which event the Holder shall be entitled to apply all rights and remedies of the Holder under the terms of this Note by reason of a default under said Other Agreement or hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">3.1.13 (a) Any material provision of either of the Pledge Agreements shall at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the Borrower, Company or any Borrower Owners, or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Borrower, Company, or any Subsidiary or any Borrower Owners or any governmental authority having jurisdiction over any of them, seeking to establish the invalidity or unenforceability thereof, or the Borrower, Company or any Subsidiary or any Borrower Owners shall deny in writing that it has any liability or obligation purported to be created under the Pledge Agreements; (b) either of the Pledge Agreements, after delivery thereof pursuant hereto, shall for any reason fail or cease to create a valid and perfected and, except to the extent permitted by the terms hereof or thereof, first priority lien and encumbrance in favor of the Holder on any collateral purported to be covered thereby.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">3.2 <u>Notification of Default.</u> Upon the occurrence of any Event of Default specified in this Article III, Company and/or Borrower shall be notified within 10 days of the occurrence/breach and will have 10 days to remedy the occurrence.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-5-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">3.3 <u>Remedies Upon Default.</u>&nbsp;Upon the occurrence of any Event of Default specified in this Article III and subject to clause 3.2, in addition to and without limitation of other remedies set forth herein in this Note, this Note shall become immediately due and payable and the Borrower shall pay to the Holder, either in form of a cash payment or as an addition to the Principal Amount and interest due under the Note an amount (the <strong>&#8220;Default Amount&#8221;)</strong> equal to (i) the Principal Amount then outstanding plus (ii) accrued and unpaid interest through the date of the Event of Default plus (iii) unaccrued interest at the Default Interest Rate through the remainder of the Note term together with all costs, including, without limitation, legal fees and expenses of collection. In addition, the Holder shall be entitled to exercise all other rights and remedies available at law or in equity, including, without limitation, those set forth in the Pledge Agreements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ARTICLE IV. MISCELLANEOUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.1 <u>Failure or Indulgence Not Waiver</u>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.2 <u>Notices</u>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, facsimile, or electronic mail addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery, upon electronic mail delivery, or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Holder,</u> <u>to</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">COSMOS HEALTH, INC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">141 West Jackson Blvd, Suite 4236</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Chicago, Illinois 60604</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attn: Grigorios Siokas</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">e-mail: <u>greg.ceo@cosmoshealthinc.com</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>with a copy (which shall not constitute notice) to:</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Davidoff Hutcher &amp; Citron LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">605 Third Avenue, 34<sup style="vertical-align:super">th</sup> Floor</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">New York, New York 10158</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Elliot H. Lutzker, Esq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: <u>ehl@dhclegal.com</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Borrower</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Cana Laboratories Holding (CYPRUS) Limited</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">12 Arsinois, Agia Marina Chrysochous, Pafos 8881, Cyprus</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Kosta Kanaroglou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">e-mail: kosta.kanaroglou@gmail.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-6-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Company:</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pharmaceutical Laboratories Cana SA</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">446 Irakliou Avenue, Iraklio Attica, 14122, Greece</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Kosta Kanaroglou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">e-mail: k.kanaroglou@cana.gr</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.3 <u>Amendments</u>. This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower, Company and the Holder. The term &#8220;<strong>Note</strong>&#8221; and all reference thereto, as used throughout this instrument, shall mean this instrument as originally executed, or if later amended or supplemented, then as so amended or supplemented.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.4 <u>Assignability</u>. This Note shall be binding upon the Borrower and Company and their respective successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.5 <u>Cost of Collection</u>. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including attorneys&#8217; fees. Such amounts spent by Holder shall be added to the Principal Amount of the Note at the time of such expenditure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.6 <u>Governing Law</u>. This Note shall be governed by and construed in accordance with the laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of New York. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state and/or federal courts located in New York. The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon <em>forum non conveniens</em>. <strong>THE BORROWER IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTIONS CONTEMPLATED HEREBY</strong>. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note or any of the Pledge Agreements by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-7-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.7 <u>Remedies</u>. The Borrower and Company each acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower and Company each acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.8 <u>Prepayment</u>. Unless an Event of Default shall occur, Borrower shall have the right at any time prior to the Maturity Date, upon thirty (30) days&#8217; notice to the Holder (the &#8220;<strong>Prepayment Notice</strong>&#8221;), to prepay the Note by making a payment to Holder equal to 100% multiplied by the sum of (i) the outstanding Principal Amount, (ii) all accrued and unpaid interest, (iii) all unaccrued interest through the remainder of the Note Term and (iv) any other amounts due under the Note (the &#8220;<strong>Prepayment Amount</strong>&#8221;). The Prepayment Notice must be received by Holder no later than 30 days prior to the date that Borrower proposes to remit the Prepayment Amount (the &#8220;<strong>Prepayment Date</strong>&#8221;). If Borrower does not remit the Prepayment Amount within two (2) days of the Prepayment Date, then (i) the Prepayment Notice and the Prepayment right granted hereunder shall be canceled and (ii) Borrower shall thereafter not be permitted to Prepay the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.9 <u>Opportunity to Consult with Counsel</u>. The Borrower and the Company represent and acknowledge that they and Borrower Owners have been provided with the opportunity to discuss and review the terms of this Note and the Pledge Agreements (as the case may be) with their respective counsel before signing this Note and the Pledge Agreements and that they and the Borrower Owners (as the case may be) are freely and voluntarily signing this Note and the Pledge Agreements in exchange for the benefits provided herein. In light of this, the Borrower, Company and the Borrower Owners will not contest the validity of this Note and the Pledge Agreements and the transactions contemplated therein. The Borrower and Company further represent and acknowledge that they and the Borrower Owners have been provided a reasonable period of time within which to review the terms of the Note and the Pledge Agreements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4.10 <u>Integration</u>. This Note, along with the Pledge Agreements, constitute the entire agreement between the parties and supersedes all prior negotiations, discussions, representations, or proposals, whether oral or written, unless expressly incorporated herein, related to the subject matter of the Note. Unless expressly provided otherwise herein, this Note may not be modified unless in writing signed by the duly authorized representatives of the Borrower, Company and the Holder. If any provision or part thereof is found to be invalid, the remaining provisions will remain in full force and effect. Additionally, Borrower and Company each agrees acknowledges that each of the Pledge Agreements are integral to the Note, and their execution by Borrower, Company and the Borrower Owners (as the case may be) and the agreement by Borrower, Company and Borrower Owners (as the case may be) to be bound by the terms therein are a material condition to the Holder&#8217;s agreement to enter into the transaction contemplated under this Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>[signature page to follow]</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>&nbsp;&nbsp; </em></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-8-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 36pt; text-align:justify;"><strong>IN WITNESS WHEREOF</strong>, Borrower, Company and Holder each have caused this Note to be signed in its name by its duly authorized officer this February 28, 2023.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 36pt; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>HOLDER:</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>COSMOS HEALTH, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp;&nbsp; </strong></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By: </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Grigorios Siokas</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td>Name: </td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Grigorios Siokas&nbsp; </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td>Title: </td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>BORROWER:</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CANA LABORATORIES HOLDING (CYPRUS) LIMITED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"><em>/s/ George Dakis </em></td> <td>&nbsp;</td> <td style="width:5%;">&nbsp;By:</td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"><em>/s/ Konstantinos-Gason Kanaroglou </em></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td>George Dakis</td> <td>&nbsp;</td> <td>&nbsp;Name: </td> <td>Konstantinos-Gaston Kanaroglou</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:</p></td> <td>Legal Representative</td> <td>&nbsp;</td> <td>&nbsp;Title: </td> <td>Owner 50% of shares</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantina-Mathilde Kanaroglou</em></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantina-Mathilde Kanaroglou</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Owner 50% of shares</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>COMPANY:</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PHARMACEUTICAL LABORATORIES CANA S.A.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp; </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantinos-Gaston Kanaroglou</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantinos-Gaston Kanaroglou</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Legal Representative&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-9-</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cosm_ex102.htm
<DESCRIPTION>CANA HOLDINGS SHARE PLEDGE AGREEMENT
<TEXT>
<html><head><title>cosm_ex102.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CANA HOLDINGS SHARE PLEDGE AGREEMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>THIS SHARE PLEDGE AGREEMENT</strong> is made as of this <strong>28<sup style="vertical-align:super">th</sup> day of February, 2023</strong> (as amended, restated, supplemented or otherwise modified from time to time, this &#8220;<strong>Agreement</strong>&#8221;), among <strong>Konstantinos-Gaston Kanaroglou</strong> and <strong>Konstantina-Mathilde Kanaroglou</strong>, (the &#8220;<strong>Pledgors</strong>&#8221; and each a &#8220;<strong>Pledgor</strong>&#8221;), <strong>Cana Laboratories Holding (Cyprus) Limited</strong> (as defined below, hereby the &#8220;<strong>Borrower</strong>&#8221;) and <strong>Cosmos Health Inc.</strong>, a corporation organized under the laws of the state of Nevada (USA) together with its successors and assigns (hereby the &#8220;<strong>Pledgee</strong>&#8221; and/or the &#8220;<strong>Holder</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>WHEREAS</strong>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A. The Pledgee has executed and delivered to <strong>Cana Laboratories Holding (Cyprus) Limited</strong>, a corporation organized under the laws of the Republic of Cyprus (the &#8220;<strong>Borrower</strong>&#8221;) that certain Secured Promissory Note dated on or about the date hereof (such note, as may be amended, supplemented, restated or modified and in effect from time to time, the &#8220;<strong>Note</strong>&#8221;) for the principal amount of <strong>Four Million One Hundred Thousand Euros</strong> (<strong>&#8364;4,100,000.00</strong>) (the &#8220;<strong>Principal Amount</strong>&#8221;). Capitalized terms that are not otherwise defined in this Agreement will have the same meaning as given to them in the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">B. Pledgors legally and beneficially own the entirety of the authorized capital stock and equity interests of Borrower (the &#8220;<strong>Shares</strong>&#8221;). To induce Pledgee to enter into the Note, Pledgors each have agreed to pledge to Pledgee all of the Shares of the Borrower now or hereafter owned or acquired by Pledgors to secure the Obligations of the Borrower under the Note. Separately, and of the same date hereof, the Borrower has agreed to provide in favor of the Pledgee a share pledge agreement over all of the shares of Pharmaceutical Laboratories Cana S.A., (the &#8220;Company&#8221;), a corporation organized under the laws of Greece (the &#8220;<strong>Cana Pharmaceuticals Share Pledge Agreement</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">C. For purposes of this Agreement, &#8220;<strong>Obligations</strong>&#8221; means all obligations, liabilities and indebtedness of every nature of Borrower from time to time owed or owing under or in respect of the Note, including, without limitation, the Principal Amount, accrued and unpaid interest, Default Interest, the Default Amount and all fees, costs and expenses heretofore, now and/or from time to time hereafter owing, due or payable by Borrower under an Even of Default.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>NOW, THEREFORE</strong>, in consideration of the premises and in order to induce Pledgee to issue the Note to Borrower and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the Pledgors and the Borrower hereby agree with Pledgee as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1. <u>Pledge</u>. Each Pledgor hereby pledges, assigns, hypothecates, transfers, delivers and grants to Pledgee a first lien on and first priority perfected security interest in and charge (&#8220;<strong>Pledge, Security Interest and Charge</strong>&#8221;) over (i) all of its ownership interests in the Shares of the Borrower now owned or hereafter acquired by a Pledgor as further described and listed in <u>Exhibit A</u> hereto (collectively, the &#8220;<strong>Pledged Shares</strong>&#8221;), (ii) all certificates, instruments, or other writings representing or evidencing the Pledged Shares, and all stock registry accounts and general intangibles arising out of, or in connection with, the Pledged Shares; and (iii) all "proceeds" as such term is defined in Section 9-102(a)(64) of the Uniform Commercial Code in effect in the State of New York on the date hereof (the &#8220;<strong>UCC</strong>&#8221;), and in Section 4 articles 169A-169E of the Cyprus Company Law (Chapter 113) and, in any event, shall include, without limitation, all dividends or other income from the Pledged Shares, collections thereon or distributions (cash, stock or otherwise) with respect thereto, including, without limitation, stock dividends, securities, cash, instruments, rights to subscribe, purchase, or sell, and other property, rights, and interest that Pledgor is at any time entitled to receive or is otherwise distributed in respect of, or in exchange for, any or all of the Pledged Shares (&#8220;<strong>Proceeds</strong>&#8221;), and without affecting the Obligations, in the event of any consolidation or merger in which the Borrower is not the surviving corporation, all shares of each class of the successor entity formed by or resulting from such consolidation or merger (the collateral described in <u>clauses (i)</u> through (iii) of this <u>Section 1</u> being collectively referred to as the &#8220;<strong>Pledged Collateral</strong>&#8221;), as collateral security for the prompt and complete payment and performance when due (whether at the stated Maturity Date, by acceleration or otherwise) of the Obligations. All of the Pledged Shares now owned by Pledgors which are presently represented by certificates are listed on <u>Exhibit A</u> hereto, which certificates, with undated assignments separate from certificates or stock/membership interest powers duly executed in blank by each Pledgor and irrevocable proxies are being delivered to Pledgee simultaneously herewith. Upon the creation or acquisition of any new Pledged Shares, each Pledgor shall execute an Addendum in the form of <u>Exhibit B</u> attached hereto (a &#8220;<strong>Pledge Addendum</strong>&#8221;). Any Pledged Collateral described in a Pledge Addendum executed by a Pledgor shall thereafter be deemed to be listed on <u>Exhibit A</u> hereto. Pledgee shall maintain possession and custody of the certificates representing the Pledged Shares and any additional Pledged Collateral.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-1-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">2. <u>Representations and Warranties and Covenants of Pledgors and Borrower</u>. Each Pledgor and the Borrower represents and warrants to Pledgee, and jointly and severally with all Pledgors covenants with Pledgee, that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a) <u>Exhibit A</u> sets forth (i) all of the Shares of the Borrower that are issued and outstanding as of the date hereof, and (iii) the percentage and number of the Shares held by Pledgor. Pledgor is the record and beneficial owner of, and has good and marketable title to those Pledged Shares indicated in <u>Exhibit A</u> as owned by Pledgor, and such Pledged Shares and all Shares of Borrower are and will remain free and clear of all pledges, liens, security interests and other encumbrances and restrictions whatsoever (&#8220;<strong>Encumbrances</strong>&#8221;), except the Pledge, Security Interest and Charge in favor of Pledgee created by this Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b) Except as set forth on <u>Exhibit A</u>, there are no outstanding options, warrants or other similar agreements with respect to the Pledged Shares or any of the other Pledged Collateral;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c) This Agreement is the legal, valid and binding obligation of Pledgor, enforceable against Pledgor to the extent of his liability as expressly stated in the present Agreement except to the extent that such enforceability is subject to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance and moratorium laws and other laws of general application affecting enforcement of creditors&#8217; rights generally, or the availability of equitable remedies, which are subject to the discretion of the court before which an action may be brought;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(d) The Pledged Shares have been duly and validly authorized and issued, are fully paid and non-assessable, and the Pledged Shares listed on <u>Exhibit A</u>, together with all other Shares listed in <u>Exhibit A</u>, constitute all of the issued and outstanding capital stock or other equity interests of the Borrower;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(e) No spousal consent or waiver, consent or waiver of the Borrower, any other Pledgor or any other shareholder, officer or director of the Borrower, consent approval or authorization of or designation or filing with any governmental or regulatory authority on the part of any Pledgor is required in connection with the (i) grant of the Pledge and security interest granted under this Agreement except as specified herein (ii) the perfection or maintenance of the Pledge and security interest created hereby except for the filing of (a) notice of pledge delivered to the Borrower unless waived by the Borrower and (b) registration of the Pledge, Security Interest and Charge created hereby with the register of shareholders of the Borrower or (iii) the exercise by Pledgor of the rights and remedies in respect of the Pledged Shares and Pledged Collateral pursuant to this Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-2-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(f) The execution, delivery and performance of this Agreement will not violate any provision of any applicable law or regulation or of any order, judgment, writ, award or decree of any court, arbitrator or governmental authority, which are applicable to any Pledgor, or of the articles or certificate of incorporation, shareholders agreement, certificate of formation, bylaws or any other similar organizational documents (&#8220;<strong>Organizational Documents</strong>&#8221;) of Pledgor or Borrower or of any Shares or other securities issued by Borrower or of any mortgage, indenture, lease, contract, or other agreement, instrument or undertaking to which any Pledgor or Borrower is a party or which is binding upon any Pledgor or the Borrower or upon any of the assets of any Pledgor or the Borrower, and will not result in the creation or imposition of any Encumbrance on or in any of the assets of any Pledgor or the Borrower, except as otherwise contemplated by this Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(g) The pledge, assignment and delivery of the Pledged Shares and the other Pledged Collateral pursuant to this Agreement creates a valid first lien on and perfected first priority Pledge, Security Interest and Charge in such Pledged Shares and Pledged Collateral and the Proceeds thereof in favor of Pledgee, subject to no right of first refusal of any shareholder of the Borrower, no prior Encumbrance or to any agreement purporting to grant to any third party a security interest or Encumbrance in the property or assets of any Pledgor or Borrower which would include the Pledged Shares or any other Pledged Collateral. Until this Agreement is terminated pursuant to <u>Section 14</u> hereof, each Pledgor covenants and agrees that it will defend, for the benefit of Pledgee, Pledgee&#8217;s right, title and security interest in and to the Pledged Shares and Pledged Collateral, and the Proceeds thereof against the claims and demands of all other persons or entities;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(h) No Pledgor nor Borrower (i) will become a person whose property or interests in property are blocked or subject to blocking pursuant to Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit or Support Terrorism (66 Fed. Reg. 49079(2001), (ii) will engage in any dealings or transactions prohibited by Section 2 of such executive order, or (iii) will otherwise become a person on the list of Specially Designated Nationals and Blocked Persons or subject to the limitations or prohibitions under any other Office of Foreign Asset Control regulation or executive order;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(i) The Borrower is the record and beneficial owner of, and has good and marketable title to all Common Shares of the Company which are duly and validly authorized and issued, are fully paid and non-assessable, and will remain free and clear of all encumbrances, except the Pledge, Security Interest and Charge in favor of Pledgee created by the Cana Pharmaceuticals Share Pledge Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(j) So long as the Borrower shall have any obligation under the Note, the Pledgors and the Borrower jointly and severally shall procure that the Borrower shall not, and the Company shall not, without the Holder&#8217;s written consent issue any new shares, convertible notes or bonds or any other securities or enter into any transaction that would result in the issuance of any new shares, convertible notes or bonds or any other securities;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(k) So long as the Borrower shall have any obligation under this Note and unless approved in writing by the Holder (which such approval not to be unreasonably withheld), the Pledgors and the Borrower jointly and severally shall procure that Borrower and Company shall not directly or indirectly: (a) change the nature of Borrower&#8217;s business or the Company&#8217;s business; (b) sell, divest, change the structure of any material assets of the Borrower, the Company or any Subsidiary other than in the ordinary course of business;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(l) So long as the Borrower shall have any obligation under the Note, the Pledgors and the Borrower jointly and severally shall procure shall not without the Holder&#8217;s written consent, the Borrower and the Company shall not use the proceeds of the Note for any other purpose other than as provided in the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-3-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">3. <u>Dividends, Distributions, Etc.</u> If, prior to irrevocable repayment in full in cash of the Obligations, any Pledgor shall receive any certificate or notice (including, without limitation, any certificate or notice representing a dividend or a distribution in connection with any reclassification, increase or reduction of capital, or issued in connection with any reorganization, merger or consolidation), or any Proceeds, options or rights, whether as an addition to, in substitution for, or in exchange for any of the Pledged Shares or otherwise, Pledgor agrees, in each case, to accept the same as Pledgee&#8217;s agent and to hold the same in trust for Pledgee, and to deliver the same promptly (but in any event within five days) to Pledgee in the exact form received, with the endorsement of Pledgor when necessary and/or with appropriate undated assignments separate from certificates or stock powers duly executed in blank to be held by Pledgee subject to the terms hereof, as additional Pledged Collateral. Each Pledgor shall promptly deliver to Pledgee (i) a Pledge Addendum with respect to such additional certificates or notices, and (ii) any financing statements or amendments to financing statements as requested by Pledgee. Each Pledgor hereby authorizes Pledgee to attach each such Pledge Addendum to this Agreement. Except as provided in <u>Section 4(b)</u> below, all sums of money and property so paid or distributed in respect of the Pledged Shares which are received by any Pledgor shall, until paid or delivered to Pledgee, be held by such Pledgor in trust for Pledgee as additional Pledged Collateral.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4. <u>Voting Rights; Dividends; Certificates</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a) So long as no Event of Default has occurred and is continuing under this Agreement, the Security Agreement or the Note (an &#8220;Event of Default&#8221;), each Pledgor shall be entitled (subject to the other provisions hereof, including, without limitation, <u>Section 9</u> below) to exercise its voting and other consensual rights with respect to the Pledged Shares and otherwise exercise the incidents of ownership thereof in any manner not inconsistent with this Agreement, the Security Agreement and the Note. Each Pledgor hereby grants to Pledgee or its nominee, an irrevocable proxy to exercise all voting, corporate and limited liability company rights relating to the Pledged Shares in any instance, which proxy shall be effective, at the discretion of Pledgee, solely upon the occurrence and during the continuance of an Event of Default. Upon the request of Pledgee at any time, each Pledgor agrees to deliver to Pledgee such further evidence of such irrevocable proxy or such further irrevocable proxies to vote the Pledged Shares as Pledgee may request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b) So long as no Event of Default shall have occurred and be continuing, each Pledgor shall be entitled to receive cash dividends or other distributions made in respect of the Pledged Shares, but only to the extent permitted to be made pursuant to the terms of the Note. Upon the occurrence and during the continuance of an Event of Default, in the event that any Pledgor, as record and beneficial owner of the Pledged Shares, shall have received or shall have become entitled to receive, any cash dividends or other distributions or Proceeds in the ordinary course, Pledgor shall deliver to Pledgee, and Pledgee shall be entitled to receive and retain, all such cash or other distributions or Proceeds as additional security for the Obligations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c) Subject to any sale or other disposition by Pledgee of the Pledged Shares and Pledged Collateral pursuant to this Agreement, upon the indefeasible full payment in cash, satisfaction and termination of all of the Obligations and the termination of this Agreement pursuant to <u>Section 15</u> hereof and of the liens and security interests hereby granted, the Pledged Shares, the other Pledged Collateral and any other property then held as part of the Pledged Collateral in accordance with the provisions of this Agreement shall be returned to such Pledgor or to such other persons or entities as shall be legally entitled thereto in their original status and along with any documents (including but not limited to certificates and proxies) provided to the Pledgee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-4-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">5. <u>Registration and Perfection of Pledge</u>. In furtherance of the grant of the Pledge, Security Interest and Charge pursuant to <u>Section 1</u> hereof, each Pledgor, until the Note is paid in full, hereby agrees as follows: (i) to give, execute, deliver, file and/or record any financing statement, notice of pledge delivered to the Borrower unless waived by the Borrower, the registration of the Pledge in the register of shareholders or at the governing website for companies (<u>www.companies.gov.cy</u>), instrument or document that may be necessary (in the reasonable judgment of Pledgee) to preserve or perfect the Pledge and security interest granted pursuant hereto or to enable Pledgee to exercise and enforce its rights hereunder with respect to such Pledge, Security Interest or Charge, including, without limitation, causing any or all of the Pledged Shares to be transferred of record into the name of Pledgee or its nominee, provided, however, that none of the foregoing shall increase such Pledgor&#8217;s liabilities or obligations or diminish such Pledgor&#8217;s rights or remedies; and (ii) during the continuance of an Event of Default which remains uncured after the expiration of applicable notice, grace and cure periods, permit representatives of Pledgee, upon reasonable notice, at any time during normal business hours to inspect and make abstracts from its books and records pertaining to the Pledged Shares and other Pledged Collateral, and permit representatives of Pledgee to be present at such Pledgor's place of business during normal business hours, upon reasonable prior written notice, to receive copies of all material communications and remittances relating to the Pledged Collateral, and forward copies of any material notices or communications received by such Pledgor with respect to the Pledged Collateral, all in such manner as Pledgee may reasonably require.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">6. <u>Obligation of the Pledgee:</u> The Pledgee shall furnish due notice of the pledge to the Borrower along with a certified copy of the share pledge agreement as article 138 2(a) of the Contract Law (Ch. 149) of Cyprus for the proper registration of the pledge to the Borrower&#8217;s records.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">7. <u>Obligation of the Pledgor and/or Borrower</u>: The Borrower upon receipt of due notice of the Pledge along with the present Pledge Agreement shall thereafter enter a Memorandum of the pledge in its register of members insofar as this relates to the shares pledged under the present Share Pledge Agreement. The Borrower&#8217;s secretary shall issue a confirmation certificate to the effect that a Memorandum of pledge, has been properly entered in the Register of Members of the Borrower. Upon the indefeasible full payment in cash, satisfaction and termination of all of the Obligations and the termination of this Agreement the Pledgee shall take such steps as may be required to restore the Pledgor&#8217;s inalienable right to the pledges share free from any encumbrances and return safely to the Pledgor all the documents originally provided.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">8. <u>Rights of Pledgee</u>. Pledgee shall not be liable for failure to collect or realize upon the Obligations or any Pledge, Security Interest and Charge hereunder, or any part thereof, or for any delay in so doing, nor shall Pledgee be under any obligation to take any action whatsoever with regard thereto. Any or all of the Pledged Shares held by Pledgee hereunder may, if an Event of Default has occurred and is continuing, with the necessary notice, be registered in the name of Pledgee or its nominee, and Pledgee or its nominee may thereafter with the necessary notice exercise all voting and corporate rights at any meeting with respect to the Borrower and exercise any and all rights of conversion, exchange, subscription or any other rights, privileges or options pertaining to any of the Pledged Shares as if it were the absolute owner thereof, including, without limitation, the right to vote in favor of, and to exchange at its discretion any and all of the Pledged Shares upon the merger, consolidation, reorganization, recapitalization or other readjustment with respect to the Borrower or upon the exercise by the Borrower, Pledgor or Pledgee of any right, privilege or option pertaining to any of the Pledged Shares, and in connection therewith, to deposit and deliver any and all of the Pledged Shares with any depository, transfer agent, registrar or other designated agency upon such terms and conditions as Pledgee may reasonably determine, all without liability except to account for property actually received by Pledgee, but Pledgee shall have no duty to exercise any of the aforesaid rights, privileges or options and shall not be responsible for any failure to do so or delay in so doing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-5-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">9. <u>Remedies</u>. Upon the occurrence and during the continuance of an Event of Default, Pledgee may exercise in respect of the Pledged Shares and other Pledged Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies attached to them, only to the extent that they are not precluded herein. Both parties understand and expressly agree that the liability of the Pledgor will be limited up to the value of the shares he/she pledged and/or up to the value recovered in a potential sale of these shares on the free market. For avoidance of any doubt, in case of an Event of Default, the Pledgor will not be held accountable and/or liable for any loss and/or damage and/or otherwise incurred by the Pledgee or any other third party. The Pledgee expressly agrees that they shall not have any other claim of any nature, personal or otherwise against the Pledgor other than the right to collect, receive, appropriate and realize upon the Pledged Shares or other Pledged Collateral as contemplated in this Agreement. Without limiting the foregoing, in case the Pledgee notifies the Pledgor of the occurrence of an Event of Default, then the Pledgee may, and will be entitled to upon the occurrence and during the continuance of an Event of Default forthwith to collect, receive, appropriate and realize upon the Pledged Shares or other Pledged Collateral, or any part thereof, and/or may forthwith date and otherwise fill in the blanks on any assignments separate from certificates or stock power or otherwise sell, assign, give an option or options to purchase, contract to sell or otherwise dispose of and deliver said Pledged Shares or other Pledged Collateral, or any part thereof, in one or more portions at one or more public or private sales or dispositions, at any exchange or broker&#8217;s board or at any of Pledgee&#8217;s offices or elsewhere upon such terms and conditions as Pledgee may deem advisable and at such prices as it may deem best, for any combination of cash and/or securities or other property or on credit or for future delivery without assumption of any credit risk, with the right to Pledgee upon any such sale, public or private, to purchase the whole or any part of said Pledged Shares so sold, free of any right or equity of redemption in any Pledgor, which right or equity is hereby expressly waived or released. Pledgee shall apply the net proceeds of any such collection, recovery, receipt, appropriation, realization, sale or disposition, after deducting all costs and expenses of every kind incurred therein or incidental to the safekeeping of any and all of the Pledged Shares or other Pledged Collateral or in any way relating to the rights of Pledgee hereunder, including reasonable attorneys&#8217; fees and legal expenses, to the payment, in whole or in part, of the Obligations, in such order as Pledgee may elect. Only after so paying over such net proceeds and after the payment by Pledgee of any other amount required by any provision of law, including, without limitation the article 134 of the Cyprus Law of Contracts (Chap. 149) or the equivalent under any Pledge Law, shall Pledgee be required to account for the surplus, if any, to any Pledgor. Each Pledgor agrees that Pledgee need not give more than ten (10) days&#8217; notice of the time and place of any public sale or of the time after which a private sale or other intended disposition is to take place and that such notice is reasonable notification of such matters. No notification need be given to any Pledgor if it has signed after default a statement renouncing or modifying any right to notification of sale or other intended disposition. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">10. <u>No Right of First Refusal</u>. Notwithstanding any provision in any Organizational Documents of Borrower, the Cyprus Companies Law or any Pledge Law to the contrary, the undersigned Pledgors, constituting all of the Shareholders of the Borrower hereby acknowledge that each Pledgor, as applicable, shall pledge to the Pledgee all of such Pledgor&#8217;s right, title and interest in the Pledged Shares and, upon any foreclosure as a result of an Event of Default, the successful bidder (which may include the Pledgee) will be deemed admitted as a shareholder of the Borrower, and will automatically succeed to all of such pledged right, title and interest, including without limitation such Pledgor&#8217;s right to vote and participate in the management and business affairs of the Borrower, right to a share of the profits and losses of the Borrower and right to receive dividends and other Proceeds from the Borrower.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-6-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">11. <u>No Disposition, Etc.</u> Until the irrevocable payment in full in cash of the Obligations, Pledgors agree that they will not sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Shares or any other Pledged Collateral, nor will any Pledgor create, incur or permit to exist any pledge or any other Encumbrance, Pledge, Security Interest and Charge with respect to any of the Pledged Shares or any other Pledged Collateral, or any interest therein, or any Proceeds thereof, except for the lien and security interest of Pledgee provided for by this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">12. <u>Sale of Pledged Interests</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a) Each Pledgor recognizes that, if Pledgee may be unable to effect a public sale or disposition (including, without limitation, any disposition in connection with a merger of the Borrower) of any or all the Pledged Shares by reason of certain prohibitions contained in any Pledge Law or other applicable laws, Pledgee may be compelled to resort to one or more private sales or dispositions thereof to a restricted group of purchasers who will be obliged to agree, among other things, to acquire such securities for their own account, for investment and not with a view to the distribution or resale thereof. Each Pledgor acknowledges and agrees that any such private sale or disposition may result in prices and other terms (including the terms of any securities or other property received in connection therewith) less favorable to the seller than if such sale or disposition were a public sale or disposition and each Pledgor agrees that it is not commercially unreasonable for Pledgee to engage in any such private sales or dispositions under such circumstances. Pledgee shall be under no obligation to delay a sale or disposition of any of the Pledged Shares in order to permit a Pledgor or the Borrower to register such securities for public sale under any Pledge Law, or under any other laws, even if a Pledgor or the Borrower would agree to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b) Each Pledgor agrees not to exercise any and all rights of subrogation it may have against the Borrower upon the sale or disposition of all or any portion of the Pledged Shares or other Pledged Collateral by Pledgee pursuant to the terms of this Agreement until the termination of this Agreement in accordance with Section 14 below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">13. <u>No Waiver; Cumulative Remedies</u>. Pledgee shall not by any act, delay, omission or otherwise be deemed to have waived any of its remedies hereunder, and no waiver by Pledgee shall be valid unless in writing and signed by Pledgee, and then only to the extent therein set forth. A waiver by Pledgee of any right or remedy hereunder on any one occasion shall not be construed as a bar to any right or remedy which Pledgee would otherwise have on any further occasion. No course of dealing between any Pledgor and Pledgee and no failure to exercise, nor any delay in exercising on the part of Pledgee of, any right, power or privilege hereunder or under the Note shall impair such right or remedy or operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided are cumulative and may be exercised singly or concurrently, and are not exclusive of any rights or remedies provided by law or in the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">14. <u>Termination</u>. This Agreement and the Pledge, Security Interest and Charge granted hereunder shall terminate and Pledgee, at the Pledgors&#8217; sole joint and several cost and expense, shall return any Pledged Shares or other Pledged Collateral then held by Pledgee in accordance with the provisions of this Agreement to Pledgors upon the termination of the Note and the full and complete performance and indefeasible satisfaction of all of the Obligations (i) in respect of the Note (including, without limitation, the indefeasible payment in full in cash of all such Obligations) and (ii) with respect to which claims have been asserted by Pledgee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-7-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">15. <u>Possession of Pledged Shares</u>. Beyond the exercise of reasonable care to assure the safe custody of the Pledged Shares in the physical possession of Pledgee pursuant hereto, neither Pledgee, nor any nominee of Pledgee, shall have any duty or liability to collect any sums due in respect thereof or to protect, preserve or exercise any rights pertaining thereto (including any duty to ascertain or take action with respect to calls, conversions, exchanges, maturities, tenders or other matters relating to the Pledged Shares and any duty to take any necessary steps to preserve rights against any parties with respect to the Pledged Shares), and shall be relieved of all responsibility for the Pledged Shares upon surrendering them to any Pledgor. Each Pledgor assumes the responsibility for being and keeping itself informed of the financial condition of the Borrower and of all other circumstances bearing upon the risk of non-payment of the Obligations, and Pledgee shall have no duty to advise any Pledgor of information known to Pledgee regarding such condition or any such circumstance. Pledgee shall have no duty to inquire into the powers of the Borrower or its officers, directors, managers, members, partners or agents thereof acting or purporting to act on its behalf.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">16. <u>Force Majeure.</u> Any Party affected by a Force Majeure and thereby prevented from performing its obligations under this Agreement shall provide reasonable notice in writing to the other Party but shall not be considered in breach of the Agreement or otherwise liable for failure or delay of completing such obligations and the obligations of the other Party shall be suspended to the same extend as of the affected Party.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">17. <u>Taxes and Expenses</u>. Pledgors and Borrower will jointly and severally pay to Pledgee within the Applicable Time Frame (as hereafter defined) (a) any taxes (excluding income taxes, franchise taxes, value-added taxes or other taxes levied on gross earnings, profits or the like of Pledgee) or registration fees payable or ruled payable by any applicable governmental authority in respect of this Agreement, together with interest and penalties, if any, and (b)all expenses, including the fees and expenses of counsel for Pledgee and of any experts and agents that Pledgee may incur in connection with (i) the administration, modification or amendment of this Agreement, (ii) the custody or preservation of, or the sale of, collection from, or other realization upon, any of the Pledged Shares, (iii) the exercise or enforcement of any of the rights of Pledgee hereunder, or (iv) the failure of any Pledgor to perform or observe any of the provisions hereof. For purposes hereof, the term &#8220;Applicable Time Frame&#8221; means the earlier of (y) ten (10) days after Pledgee&#8217;s written demand for such payment and (z) the date set forth in Pledgee&#8217;s written demand for such payment if such payment is required to be made by Pledgee prior to the ten (10) day period referred to in the foregoing clause &#8220;(z)&#8221;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">18. <u>Governing Law; Jurisdiction; Jury Trial</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of Cyprus, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than Cyprus. Each party hereby irrevocably submits to the exclusive jurisdiction of Greece and specifically the Athenian courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">19. <u>Counterparts</u>. This Agreement may be executed in two or more identical counterparts, all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile, .pdf or similar electronically transmitted signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-8-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">20. <u>Headings</u>. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">21. <u>Severability</u>. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">22. <strong><u>ENTIRE AGREEMENT; AMENDMENTS</u></strong><strong>. THIS AGREEMENT, TOGETHER WITH THE OTHER LOAN DOCUMENTS, SUPERSEDES ALL OTHER PRIOR ORAL OR WRITTEN AGREEMENTS BETWEEN ANY PLEDGOR, PLEDGEE, THEIR AFFILIATES AND PERSONS ACTING ON THEIR BEHALF WITH RESPECT TO THE MATTERS DISCUSSED HEREIN, AND THIS AGREEMENT, TOGETHER WITH THE NOTE AND THE OTHER INSTRUMENTS REFERENCED HEREIN AND THEREIN, CONTAIN THE ENTIRE UNDERSTANDING OF THE PARTIES WITH RESPECT TO THE MATTERS COVERED HEREIN AND THEREIN AND, EXCEPT AS SPECIFICALLY SET FORTH HEREIN OR THEREIN, NEITHER THE PLEDGEE NOR ANY PLEDGOR MAKES ANY REPRESENTATION, WARRANTY, COVENANT OR UNDERTAKING WITH RESPECT TO SUCH MATTERS. AS OF THE DATE OF THIS AGREEMENT, THERE ARE NO UNWRITTEN AGREEMENT BETWEEN THE PARTIES WITH RESPECT TO THE MATTERS DISCUSSED HEREIN. EXCEPT AS SET FORTH IN SECTION 1 HEREOF, NO PROVISION OF THIS AGREEMENT MAY BE AMENDED, MODIFIED OR SUPPLEMENTED OTHER THAN BY AN INSTRUMENT IN WRITING SIGNED BY THE PLEDGOR AND PLEDGEE</strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">23. <u>Notices</u>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, facsimile, or electronic mail addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery, upon electronic mail delivery, or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Pledgee, to</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">COSMOS HEALTH INC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">141 West Jackson Blvd, Suite 4236</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Chicago, Illinois 60604</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attn: Grigorios Siokas</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">e-mail: <u>greg.ceo@cosmoshealthinc.com</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>with a copy (which shall not constitute notice) to</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Davidoff Hutcher &amp; Citron LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">605 Third Avenue, 34<sup style="vertical-align:super">th</sup> Floor</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">New York, New York 10158</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Elliot H. Lutzker, Esq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: <u>ehl@dhclegal.com</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-9-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Borrower</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Cana Laboratories Holding (CYPRUS) Limited</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">12 Arsinois, Agia Marina Chrysochous, Pafos 8881, Cyprus</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Kosta Kanaroglou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">e-mail: kosta.kanaroglou@gmail.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Pledgors</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pharmaceutical Laboratories Cana SA</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">446 Irakliou Avenue, Iraklio Attica, 14122, Greece</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Kosta Kanaroglou and Konstantina Kanaroglou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: k.kanaroglou@cana.gr and konstantinac@gmail.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">24. <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of the Note. No Pledgor shall assign this Agreement or any rights or obligations hereunder without the prior written consent of Pledgee. Pledgee may assign its rights hereunder without the consent of Pledgor, in which event such assignee shall be deemed to be Pledgee hereunder with respect to such assigned rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">25. <u>No Third Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">26. <u>Surviva</u>l. All representations, warranties, covenants and agreements of the Pledgors and Pledgee shall survive the execution and delivery of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">27. <u>Further Assurances</u>. Each Pledgor agrees that it will, at any time and from time to time upon the written request of Pledgee, execute and deliver all assignments separate from certificates or stock powers, financing statements, notices, registrations, and such further documents and do such further acts and things as Pledgee may reasonably request consistent with the provisions hereof in order to carry out the intent and accomplish the purpose of this Agreement and the consummation of the transactions contemplated hereby.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">28. <u>No Strict Construction</u>. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">29. <u>Pledgee Authorized</u>. Each Pledgor hereby authorizes Pledgee to file one or more financing or continuation statements, notices, registrations and amendments thereto (or similar documents required by any laws of any applicable jurisdiction) relating to all or any part of the Pledged Shares or other Pledged Collateral and the Pledge, Security Interest and Charge created hereunder without the signature of any Pledgor.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">30. <u>Borrower Acknowledgement</u>. Borrower hereby acknowledges receipt of an executed copy of this Agreement and waives any requirement for a notice from the Pledgors or Pledgee regarding same. The Borrower hereby agrees and Pledgors hereby covenant that they shall procure, that the Borrower shall promptly to record on its books and records as required under applicable law the grant of the Pledge, Security Interest and Charge over the Pledged Shares, and they will delivered to the Pledgee the necessary certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<strong>Signature Page Follows</strong>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-10-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">IN WITNESS WHEREOF, the parties hereto have caused this Pledge Agreement to be duly executed and delivered individually or by their duly authorized officer (as the case may be) on the date first above written.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>PLEDGEE</u></strong>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>COSMOS HEALTH INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp;&nbsp; </strong></p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"><em>/s/ Grigorios Siokas </em></td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td>Grigorios Siokas </td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>Title: </td> <td>Chief Executive Officer</td> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; &nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><u>PLEDGORS</u></strong>:&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><u>BORROWER</u></strong>:</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><strong>CANA LABORATORIES HOLDING (CYPRUS) LIMITED</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:5%;">By:</td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;">&nbsp;<em>/s/ Konstantinos-Gaston Kanaroglou</em> </td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:5%;">By:</td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;">&nbsp;<em>/s/ Konstantinos-Gaston Kanaroglou</em></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantinos-Gaston Kanaroglou</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantinos-Gaston Kanaroglou</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Owner</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantina-Mathilde Kanaroglou</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantina-Mathilde Kanaroglou</em></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantina-Mathilde Kanaroglou</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantina-Mathilde Kanaroglou</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Owner</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ George Dakis</em></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">George Dakis</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Legal Representative</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>WITNESSES</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1. Sign:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Nikolaos Diakoniarakis</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2. Sign: </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/Argyro Vidou</em></p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name and Address</strong>:&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name and Address</strong>:</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Nikolaos Diakoniarakis&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Argyro Vidou&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ID: &#913;&#918; 050484&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">ID: AK 809371&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">C/O DBS Global&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">C/O DBS Global&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">67 Iraklitou Av.&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">67 Iraklitou Av.&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patima Chalandriou 152 38&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patima Chalandriou 152 38&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Greece&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Greece&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-11-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT A</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>to Pledge Agreement</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Description of Pledged Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Pledgor</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Class</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Stock Certificate No.</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Percentage and Number of Stock Held by Pledgor</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantinos-Gaston, Kanaroglou</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Ordinary</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1 &#8211; 25.000</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantina-Mathilde, Kanaroglou</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Ordinary</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">26.001 &#8211; 50.000</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">50</td> <td style="vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">100</td> <td style="vertical-align:bottom;white-space: nowrap;">%</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-12-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EXHIBIT B</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>to&nbsp;Pledge Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Addendum to Pledge Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The undersigned, being the Pledgor pursuant to that certain Pledge Agreement dated as of February 28<sup style="vertical-align:super">th</sup>, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<strong>Pledge Agreement</strong>&#8221;) in favor of&nbsp;<strong>Cosmos Health Inc.</strong>, a Nevada corporation (&#8220;<strong>Pledgee</strong>&#8221;), by executing this Addendum, hereby acknowledges that Pledgor has acquired and legally and beneficially owns all of the issued and outstanding [shares of capital stock ] described below (the &#8220;<strong>Shares</strong>&#8221;) of&nbsp;<strong>Cana Laboratories Holding (Cyprus) Limited</strong>, a corporation organized under the laws of the Republic of Cyprus (&#8220;<strong>Borrower</strong>&#8221;).&nbsp;&nbsp;Pledgor hereby agrees and acknowledges that the Shares shall be deemed Pledged Shares pursuant to the Pledge Agreement.&nbsp;&nbsp;Pledgor hereby represents and warrants to Pledgee that (i) all of the Shares of the Borrower now owned by Pledgor is presently represented by the certificates listed below, which certificates, with undated assignments separate from certificate or stock powers duly executed in blank by Pledgor, are being delivered to Pledgee, simultaneously herewith (or have been previously delivered to Pledgee), and (ii) after giving effect to this addendum, the representations and warranties set forth in&nbsp;<u>Section 3</u>&nbsp;of the Pledge Agreement are true, complete and correct as of the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Pledged Shares</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Name of the Pledgor</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Class of Equity Interest</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Certificate No.</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Percentage of Shares Held by Pledgor</strong></p></td> <td style="width:1%;"><strong>&nbsp;</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-13-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">IN WITNESS WHEREOF, Pledgor has executed this Addendum this ___ day of ________, 202___.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">By:&nbsp;&nbsp;______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name: Konstantinos-Gaston Kanaroglou&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">By:&nbsp;&nbsp;______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name: Konstantina-Mathilde Kanaroglou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-14-</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>cosm_ex103.htm
<DESCRIPTION>CANA PHARMACEUTICAL SHARE PLEDGE AGREEMENT
<TEXT>
<html><head><title>cosm_ex103.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CANA PHARMACEUTICALS SHARE PLEDGE AGREEMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>THIS SHARE PLEDGE AGREEMENT</strong> is made as of this <strong>28<sup style="vertical-align:super">th</sup> day of February, 2023</strong> (as amended, restated, supplemented or otherwise modified from time to time, this &#8220;<strong>Agreement</strong>&#8221;) among <strong>Cana Laboratories Holding (Cyprus) Limited</strong>, a corporation organized under the laws of the Republic of Cyprus (the &#8220;<strong>Pledgor</strong>&#8221;) and <strong>Cosmos Health Inc.</strong>, a corporation organized under the laws of the state of Nevada (USA) together with its successors and assigns (the &#8220;<strong>Pledgee</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>WHEREAS:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A. The Pledgee has executed and delivered to Pledgor that certain Secured Promissory Note dated on or about the date hereof (such note, as may be amended, supplemented, restated or modified and in effect from time to time, the &#8220;<strong>Note</strong>&#8221;) for the principal amount of <strong>Four Million One Hundred Thousand Euros (&#8364;4,100,000.00</strong> ) (the &#8220;<strong>Principal Amount</strong>&#8221;). Capitalized terms that are not otherwise defined in this Agreement will have the same meaning as given to them in the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">B. Pledgor legally and beneficially owns the entirety of the authorized capital stock and equity interests (&#8220;<strong>Shares</strong>&#8221;) of <strong>Pharmaceutical Laboratories Cana S.A.</strong>, a corporation organized under the laws of Greece (the &#8220;<strong>Company</strong>&#8221;). To induce Pledgee to enter into the Note, Pledgor has agreed to pledge to Pledgee all of the Shares of the Company now or hereafter owned or acquired by Pledgor to secure the Obligations of the Borrower under the Note. For purposes of this Agreement, &#8220;<strong>Obligations</strong>&#8221; means all obligations, liabilities and indebtedness of every nature of Pledgor from time to time owed or owing under or in respect of the Note, including, without limitation, the Principal Amount, accrued and unpaid interest, Default Interest, the Default Amount and all fees, costs and expenses heretofore, now and/or from time to time hereafter owing, due or payable by Pledgor under an Even of Default. The Company, as further inducement for the Pledgee, also has agreed to be bound as a party by certain covenants in this Agreement. As additional inducement, the owners of all shares of the Pledgor also have pledged their shares in favor of Pledgee pursuant to a share pledge agreement of same date (the &#8220;<strong>Cana Holdings Share Pledge Agreement</strong>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>NOW, THEREFORE</strong>, in consideration of the premises and in order to induce Pledgee to issue the Note and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Pledgor and the Company hereby agree with Pledgee as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">1. <u>Pledge</u>. Pledgor hereby pledges, assigns, hypothecates, transfers, delivers and grants to Pledgee a first lien on and first priority perfected security interest in and charge (&#8220;Pledge, Security Interest and Charge&#8221;) over (i) all of its ownership interests of 100% of the Shares of the Company now owned or hereafter acquired by Pledgor as further described and listed in <u>Exhibit A</u> hereto (collectively, the &#8220;Pledged Shares&#8221;), (ii) all certificates, instruments, or other writings representing or evidencing the Pledged Shares, and all stock registry accounts and general intangibles arising out of, or in connection with, the Pledged Shares; and (iii) all "proceeds" as such term is defined in Section 9-102(a)(64) of the Uniform Commercial Code in effect in the State of New York on the date hereof (the &#8220;UCC&#8221;), the article 1221 of the Greek Civil Code and in addition the section ten, articles 158-163 of the 4548/2018 legislation - (allocation of profits) and, in any event, shall include, without limitation, all dividends or other income from the Pledged Shares, collections thereon or distributions (cash, stock or otherwise) with respect thereto, including, without limitation, stock dividends, securities, cash, instruments, rights to subscribe, purchase, or sell, and other property, rights, and interest that Pledgor is at any time entitled to receive or is otherwise distributed in respect of, or in exchange for, any or all of the Pledged Shares (&#8220;Proceeds&#8221;), and without affecting the Obligations, in the event of any consolidation or merger in which the Company is not the surviving corporation, all shares of each class of the successor entity formed by or resulting from such consolidation or merger (the collateral described in <u>clauses (i)</u> through (iii) of this <u>Section 1</u> being collectively referred to as the &#8220;Pledged Collateral&#8221;), as collateral security for the prompt and complete payment and performance when due (whether at the stated Maturity Date, by acceleration or otherwise) of the Obligations. All of the Pledged Shares now owned by Pledgor which are presently represented by certificates are listed on <u>Exhibit A</u> hereto, which certificates, with undated assignments separate from certificates or stock/membership interest powers duly executed in blank by Pledgor and irrevocable proxies, are being delivered to Pledgee simultaneously herewith. Upon the creation or acquisition of any new Pledged Shares, Pledgor shall execute an Addendum in the form of <u>Exhibit B</u> attached hereto (a &#8220;Pledge Addendum&#8221;). Any Pledged Collateral described in a Pledge Addendum executed by Pledgor shall thereafter be deemed to be listed on <u>Exhibit A</u> hereto. Pledgee shall maintain possession and custody of the certificates representing the Pledged Shares and any additional Pledged Collateral.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-1-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">2. <u>Representations and Warranties of Pledgor</u>. Pledgor and Company each represents and warrants to Pledgee, and jointly and severally covenant with Pledgee, that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a) <u>Exhibit A</u> sets forth (i) all of the Pledged Shares, constituting 100% of the Shares of the Company that are issued and outstanding as of the date hereof, and (ii) that Pledgor is the record and beneficial owner of, and has good and marketable title to all of the Pledged Shares; and such Pledged Shares are and will remain free and clear of all pledges, liens, security interests and other encumbrances and restrictions whatsoever (&#8220;Encumbrances&#8221;), except the Pledge, Security Interest and Charge in favor of Pledgee created by this Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b) Except as set forth on <u>Exhibit A</u>, there are no outstanding options, warrants or other similar agreements with respect to the Pledged Shares or any of the other Pledged Collateral;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c) This Agreement is the legal, valid and binding obligation of Pledgor and the Company, enforceable against Pledgor and the Company in accordance with its terms except to the extent that such enforceability is subject to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance and moratorium laws and other laws of general application affecting enforcement of creditors&#8217; rights generally, or the availability of equitable remedies, which are subject to the discretion of the court before which an action may be brought;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(d) The Pledged Shares have been duly and validly authorized and issued, are fully paid and non-assessable, and the Pledged Shares constitute all of the issued and outstanding capital stock or other equity interests of the Company;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(e) No consent or waiver of the Company, Pledgor or any other shareholder, officer or director of the Company, consent approval or authorization of or designation or filing with any governmental or regulatory authority on the part of Pledgor is required in connection with the (i) grant of the Pledge and security interest granted under this Agreement except as specified herein (ii) the perfection or maintenance of the Pledge and Pledge, Security Interest and Charge created hereby except for the filing of (a) financing statements as required by the UCC (b) a notice of pledge delivered to the Company unless waived by the Company and (c) registration of the Pledge, Security Interest and Charge created hereby with the register of shareholders of the Company or (iii) the exercise by Pledgor of the rights and remedies in respect of the Pledged Shares and Pledged Collateral pursuant to this Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-2-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(f) The execution, delivery and performance of this Agreement will not violate any provision of any applicable law or regulation or of any order, judgment, writ, award or decree of any court, arbitrator or governmental authority, which are applicable to Pledgor or Company, or of the articles or certificate of incorporation, shareholders agreement, certificate of formation, bylaws or any other similar organizational documents (&#8220;Organizational Documents&#8221;) of Pledgor or Company or of any Shares or other securities issued by the Company or of any mortgage, indenture, lease, contract, or other agreement, instrument or undertaking to which Pledgor or Company is a party or which is binding upon Pledgor or the Company or upon any of the assets of any Pledgor or the Company, and will not result in the creation or imposition of any Encumbrance on or in any of the assets of Pledgor or the Company, except as otherwise contemplated by this Agreement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(g) The pledge, assignment and delivery of the Pledged Shares and the other Pledged Collateral pursuant to this Agreement creates a valid first lien on and perfected first priority Pledge, Security Interest and Charge in such Pledged Shares and Pledged Collateral and the Proceeds thereof in favor of Pledgee, subject to no right of first refusal of any shareholder of the Company, no prior Encumbrance or to any agreement purporting to grant to any third party a security interest or Encumbrance in the property or assets of Pledgor or Company which would include the Pledged Shares or any other Pledged Collateral. Until this Agreement is terminated pursuant to <u>Section 12</u> hereof, Pledgor covenants and agrees that it will defend, for the benefit of Pledgee, Pledgee&#8217;s right, title and security interest in and to the Pledged Shares and Pledged Collateral, and the Proceeds thereof against the claims and demands of all other persons or entities; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(h) Neither Pledgor nor Company (i) will become a person whose property or interests in property are blocked or subject to blocking pursuant to Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit or Support Terrorism (66 Fed. Reg. 49079(2001), (ii) will engage in any dealings or transactions prohibited by Section 2 of such executive order, or (iii) will otherwise become a person on the list of Specially Designated Nationals and Blocked Persons or subject to the limitations or prohibitions under any other Office of Foreign Asset Control regulation or executive order;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(i) So long as the Pledgor shall have any obligation under the Note, the Company shall not, without the Holder&#8217;s written consent issue any new shares, convertible notes or bonds or any other securities or enter into any transaction that would result in the issuance of any new shares, convertible notes or bonds or any other securities;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(j) So long as the Pledgor shall have any obligation under this Note and unless approved in writing by the Holder (which such approval not to be unreasonably withheld), Pledgor and Company shall not directly or indirectly: (a) change e nature of Pledgor&#8217;s business or the Company&#8217;s business; (b) sell, divest, change the structure of any material assets of the Borrower, the Company or any Subsidiary other than in the ordinary course of business;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(k) So long as the Pledgor shall have any obligation under the Note, the Pledgor and the Company shall not, without the Holder&#8217;s written consent, use the proceeds of the Note for any other purpose other than as provided in the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">3. <u>Dividends, Distributions, Etc.</u> If, prior to irrevocable repayment in full in cash of the Obligations, Pledgor shall receive any certificate or notice (including, without limitation, any certificate or notice representing a dividend or a distribution in connection with any reclassification, increase or reduction of capital, or issued in connection with any reorganization, merger or consolidation), or any Proceeds, options or rights, whether as an addition to, in substitution for, or in exchange for any of the Pledged Shares or otherwise, Pledgor agrees, in each case, to accept the same as Pledgee&#8217;s agent and to hold the same in trust for Pledgee, and to deliver the same promptly (but in any event within five days) to Pledgee in the exact form received, with the endorsement of Pledgor when necessary and/or with appropriate undated assignments separate from certificates or stock powers duly executed in blank, to be held by Pledgee subject to the terms hereof, as additional Pledged Collateral. Pledgor shall promptly deliver to Pledgee (i) a Pledge Addendum with respect to such additional certificates or notices, and (ii) any financing statements or amendments to financing statements as requested by Pledgee. Pledgor hereby authorizes Pledgee to attach each such Pledge Addendum to this Agreement. Except as provided in <u>Section 4(b)</u> below, all sums of money and property so paid or distributed in respect of the Pledged Shares which are received by Pledgor shall, until paid or delivered to Pledgee, be held by Pledgor in trust for Pledgee as additional Pledged Collateral.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-3-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">4. <u>Voting Rights; Dividends; Certificates</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a) So long as no Event of Default has occurred and is continuing under this Agreement, the Cana Holdings Share Pledge Agreement or the Note (an &#8220;Event of Default&#8221;), Pledgor shall be entitled (subject to the other provisions hereof, including, without limitation, <u>Section 7</u> below) to exercise its voting and other consensual rights with respect to the Pledged Shares and otherwise exercise the incidents of ownership thereof in any manner not inconsistent with this Agreement, the Security Agreement and the Note. Pledgor hereby grants to Pledgee or its nominee, an irrevocable proxy to exercise all voting, corporate and limited liability company rights relating to the Pledged Shares in any instance, which proxy shall be effective, at the discretion of Pledgee, solely upon the occurrence and during the continuance of an Event of Default. Upon the request of Pledgee at any time, Pledgor agrees to deliver to Pledgee such further evidence of such irrevocable proxy or such further irrevocable proxies to vote the Pledged Shares as Pledgee may request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b) So long as no Event of Default shall have occurred and be continuing, Pledgor shall be entitled to receive cash dividends or other distributions made in respect of the Pledged Shares, but only to the extent permitted to be made pursuant to the terms of the Note. Upon the occurrence and during the continuance of an Event of Default, in the event that Pledgor, as record and beneficial owner of the Pledged Shares, shall have received or shall have become entitled to receive, any cash dividends or other distributions or Proceeds in the ordinary course, Pledgor shall deliver to Pledgee, and Pledgee shall be entitled to receive and retain, all such cash or other distributions or Proceeds as additional security for the Obligations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c) Subject to any sale or other disposition by Pledgee of the Pledged Shares and Pledged Collateral pursuant to this Agreement, upon the indefeasible full payment in cash, satisfaction and termination of all of the Obligations and the termination of this Agreement pursuant to <u>Section 12</u> hereof and of the liens and security interests hereby granted, the Pledged Shares, the other Pledged Collateral and any other property then held as part of the Pledged Collateral in accordance with the provisions of this Agreement shall be returned to Pledgor or to such other persons or entities as shall be legally entitled thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">5. <u>Registration and Perfection of Pledge</u>. In furtherance of the grant of the Pledge, Security Interest and Charge pursuant to <u>Section 1</u> hereof, Pledgor, until the Note is paid in full, hereby agrees as follows: (i) to give, execute, deliver, file and/or record any financing statement, notice of pledge delivered to the Company unless waived by the Company, any registration of the Pledge in the register of shareholders the Company or at the governing website for companies (<u>www.businessportal.gr</u>) instrument or document that may be necessary (in the reasonable judgment of Pledgee) to preserve or perfect the Pledge, Security Interest and Charge granted pursuant hereto or to enable Pledgee to exercise and enforce its rights hereunder with respect to such Pledge, Security Interest or Charge, including, without limitation, causing any or all of the Pledged Shares to be transferred of record into the name of Pledgee or its nominee, provided, however, that none of the foregoing shall increase Pledgor&#8217;s liabilities or obligations or diminish Pledgor&#8217;s rights or remedies; and (ii) during the continuance of an Event of Default which remains uncured after the expiration of applicable notice, grace and cure periods, permit representatives of Pledgee, upon reasonable notice, at any time during normal business hours to inspect and make abstracts from its books and records pertaining to the Pledged Shares and other Pledged Collateral, and permit representatives of Pledgee to be present at Pledgor's place of business during normal business hours, upon reasonable prior written notice, to receive copies of all material communications and remittances relating to the Pledged Collateral, and forward copies of any material notices or communications received by Pledgor with respect to the Pledged Collateral, all in such manner as Pledgee may reasonably require.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-4-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">6. <u>Remedies</u>. Upon the occurrence and during the continuance of an Event of Default, Pledgee may exercise in respect of the Pledged Shares and other Pledged Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of a secured party under the Uniform Commercial Code, the Greek Civil Code (art. 1237) and the Greek Civil Procedure Code.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">7. <u>No Right of First Refusal</u>. Notwithstanding any provision in any Organizational Documents of the Company, the laws of Greece or any Pledge Law to the contrary, the Pledgor, as sole shareholder of the Company, hereby acknowledges that, upon any foreclosure as a result of an Event of Default, the successful bidder (which may include the Pledgee) will be deemed admitted as a shareholder of the Company, and will automatically succeed to all of such pledged right, title and interest, including without limitation such Pledgor&#8217;s right to vote and participate in the management and business affairs of the Company, right to a share of the profits and losses of the Company and right to receive dividends and other Proceeds from the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">8. <u>No Disposition, Etc.</u> Until the irrevocable payment in full in cash of the Obligations, Pledgor agrees that it will not sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Shares or any other Pledged Collateral, nor will Pledgor create, incur or permit to exist any pledge or any other Encumbrance, Pledge, Security Interest and Charge with respect to any of the Pledged Shares or any other Pledged Collateral, or any interest therein, or any Proceeds thereof, except for the Pledge, Security Interest and Charge provided for by this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">9. <u>No Waiver; Cumulative Remedies</u>. Pledgee shall not by any act, delay, omission or otherwise be deemed to have waived any of its remedies hereunder, and no waiver by Pledgee shall be valid unless in writing and signed by Pledgee, and then only to the extent therein set forth. A waiver by Pledgee of any right or remedy hereunder on any one occasion shall not be construed as a bar to any right or remedy which Pledgee would otherwise have on any further occasion. No course of dealing between Pledgor and Pledgee and no failure to exercise, nor any delay in exercising on the part of Pledgee of, any right, power or privilege hereunder or under the Note shall impair such right or remedy or operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided are cumulative and may be exercised singly or concurrently, and are not exclusive of any rights or remedies provided by law or in the Note.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">10. <u>Termination</u>. This Agreement and the Pledge, Security Interest and Charge granted hereunder shall terminate and Pledgee, at the Pledgor&#8217;s and Company&#8217;s cost and expense, shall return any Pledged Shares or other Pledged Collateral then held by Pledgee in accordance with the provisions of this Agreement to Pledgor upon the termination of the Note and the full and complete performance and indefeasible satisfaction of all of the Obligations (i) in respect of the Note (including, without limitation, the indefeasible payment in full in cash of all such Obligations) and (ii) with respect to which claims have been asserted by Pledgee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-5-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">11. <u>Possession of Pledged Shares</u>. Beyond the exercise of reasonable care to assure the safe custody of the Pledged Shares in the physical possession of Pledgee pursuant hereto, neither Pledgee, nor any nominee of Pledgee, shall have any duty or liability to collect any sums due in respect thereof or to protect, preserve or exercise any rights pertaining thereto (including any duty to ascertain or take action with respect to calls, conversions, exchanges, maturities, tenders or other matters relating to the Pledged Shares and any duty to take any necessary steps to preserve rights against any parties with respect to the Pledged Shares), and shall be relieved of all responsibility for the Pledged Shares upon surrendering them to Pledgor. Pledgor assumes the risk of non-payment of the Obligations, and Pledgee shall have no duty to advise Pledgor of information known to Pledgee regarding such condition or any such circumstance. Pledgee shall have no duty to inquire into the powers of the Company or its officers, directors, managers, members, partners or agents thereof acting or purporting to act on its behalf.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">12. <u>Taxes and Expenses</u>. Pledgor and Company jointly and severally will pay to Pledgee within the Applicable Time Frame (as hereafter defined) (a) any taxes (excluding income taxes, franchise taxes, value-added taxes or other taxes levied on gross earnings, profits or the like of Pledgee) or registration fees payable or ruled payable by any applicable governmental authority in respect of this Agreement, together with interest and penalties, if any, and (b) all expenses, including the fees and expenses of counsel for Pledgee and of any experts and agents that Pledgee may incur in connection with (i) the administration, modification or amendment of this Agreement, (ii) the custody or preservation of, or the sale of, collection from, or other realization upon, any of the Pledged Shares, (iii) the exercise or enforcement of any of the rights of Pledgee hereunder, or (iv) the failure of Pledgor or Company to perform or observe any of the provisions hereof. For purposes hereof, the term &#8220;<strong>Applicable Time Frame</strong>&#8221; means the earlier of (y) ten (10) days after Pledgee&#8217;s written demand for such payment and (z) the date set forth in Pledgee&#8217;s written demand for such payment if such payment is required to be made by Pledgee prior to the ten (10) day period referred to in the foregoing clause &#8220;(z)&#8221;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">13. <u>Governing Law; Jurisdiction; Jury Trial</u>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of Greece, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than Greece. Each party hereby irrevocably submits to the exclusive jurisdiction of Greece and specifically the Athenian courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Notwithstanding the foregoing, the Pledgee may enforce its rights and remedies in any other jurisdiction applicable to the Pledged Shares or other Pledged Collateral.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">14. <u>Counterparts</u>. This Agreement may be executed in two or more identical counterparts, all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile, .pdf or similar electronically transmitted signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">15. <u>Headings</u>. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">16. <u>Severability</u>. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-6-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">17. <strong><u>ENTIRE AGREEMENT; AMENDMENTS</u></strong><strong>. THIS AGREEMENT, TOGETHER WITH THE OTHER LOAN DOCUMENTS, SUPERSEDES ALL OTHER PRIOR ORAL OR WRITTEN AGREEMENTS BETWEEN ANY PLEDGOR, PLEDGEE, COMPANY, THEIR AFFILIATES AND PERSONS ACTING ON THEIR BEHALF WITH RESPECT TO THE MATTERS DISCUSSED HEREIN, AND THIS AGREEMENT, TOGETHER WITH THE NOTE AND THE OTHER INSTRUMENTS REFERENCED HEREIN AND THEREIN, CONTAIN THE ENTIRE UNDERSTANDING OF THE PARTIES WITH RESPECT TO THE MATTERS COVERED HEREIN AND THEREIN AND, EXCEPT AS SPECIFICALLY SET FORTH HEREIN OR THEREIN, PLEDGEE, PLEDGOR AND COMPANY MAKE NO REPRESENTATION, WARRANTY, COVENANT OR UNDERTAKING WITH RESPECT TO SUCH MATTERS. AS OF THE DATE OF THIS AGREEMENT, THERE ARE NO UNWRITTEN AGREEMENT BETWEEN THE PARTIES WITH RESPECT TO THE MATTERS DISCUSSED HEREIN. EXCEPT AS SET FORTH IN SECTION 1 HEREOF, NO PROVISION OF THIS AGREEMENT MAY BE AMENDED, MODIFIED OR SUPPLEMENTED OTHER THAN BY AN INSTRUMENT IN WRITING SIGNED BY THE PLEDGOR, COMPANY AND PLEDGEE</strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">18. <u>Notices</u>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, facsimile, or electronic mail addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery, upon electronic mail delivery, or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Pledgee, to</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>COSMOS HEALTH INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">141 West Jackson Blvd, Suite 4236</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Chicago, Illinois 60604</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attn: Grigorios Siokas</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">e-mail: greg.ceo@cosmoshealthinc.com </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>with a copy (which shall not constitute notice) to</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Davidoff Hutcher &amp; Citron LLP</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">605 Third Avenue, 34<sup style="vertical-align:super">th</sup> Floor</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">New York, New York 10158</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Elliot H. Lutzker, Esq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: ehl@dhclegal.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-7-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Pledgors</u>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Konstantinos-Gaston Kanaroglou</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">22 Diligianni Street, Kifisia</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">14561 Attica, Greece</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: kosta.kanaroglou@gmail.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Konstantina-Mathilde Kanaroglou</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">29 Mavromichali Street, Kifisia</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">14562 Attica, Greece</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: konstantinac@gmail.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u>If to the Company:</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Pharmaceutical Laboratories Cana SA</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">446 Irakliou Avenue, Iraklio Attica, 14122, Greece</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Attention: Kosta Kanaroglou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Email: k.kanaroglou@cana.gr</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">19. <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of the Note. Neither Pledgor nor Company shall assign this Agreement or any rights or obligations hereunder without the prior written consent of Pledgee. Pledgee may assign its rights hereunder without the consent of Pledgor or Company, in which event such assignee shall be deemed to be Pledgee hereunder with respect to such assigned rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">20. <u>No Third Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">21. <u>Surviva</u>l. All representations, warranties, covenants and agreements of the Pledgor, Company and Pledgee shall survive the execution and delivery of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">22. <u>Further Assurances</u>. Pledgor agrees that it will, at any time and from time to time upon the written request of Pledgee, execute and deliver all assignments separate from certificates or stock powers, financing statements, notices, registrations, and such further documents and do such further acts and things as Pledgee may reasonably request consistent with the provisions hereof in order to carry out the intent and accomplish the purpose of this Agreement and the consummation of the transactions contemplated hereby.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">23. <u>No Strict Construction</u>. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">24. <u>Pledgee Authorized</u>. Pledgor hereby authorizes Pledgee to file one or more financing or continuation statements, notices, registrations and amendments thereto (or similar documents required by any laws of any applicable jurisdiction) relating to all or any part of the Pledged Shares or other Pledged Collateral and the Pledge, Security Interest and Charge created hereunder without the signature of Pledgor.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">25. <u>Company Acknowledgement</u>. Company hereby acknowledges receipt of an executed copy of this Agreement and waives any requirement for a notice from the Pledgor or Pledgee regarding same. The Company hereby agrees and Pledgor hereby covenants that it shall procure, that the Company shall promptly to record on its books and records as required under applicable law the grant of the Pledge, Security Interest and Charge over the Pledged Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>[Signature Page Follows]</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-8-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">IN WITNESS WHEREOF, the parties hereto have caused this Pledge Agreement to be duly executed and delivered individually or by their duly authorized officer (as the case may be) on the date first above written.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong style="MARGIN: 0px"><u>PLEDGOR</u></strong>:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CANA LABORATORIES HOLDING (CYPRUS) LIMITED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp; </strong></p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp; &nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ George Dakis&nbsp;</em></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantinos-Gaston Kanaroglou&nbsp;</em></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">George Dakis&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantinos-Gaston Kanaroglou&nbsp;&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Legal Representative&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Owner&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantina-Mathilde Kanaroglou&nbsp;</em></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantina-Mathilde Kanaroglou&nbsp;&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Owner&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><u>PLEDGEE</u></strong>:</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><strong>COSMOS HEALTH INC.</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp; </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Grigorios Siokas</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Grigorios Siokas&nbsp; </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>COMPANY</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PHARMACEUTICAL LABORATORIES CANA S.A.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp; </strong></p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:&nbsp; </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Konstantinos-Gaston Kanaroglou</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name: </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Konstantinos-Gaston Kanaroglou</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title: </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Legal Representative</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-9-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u><strong>EXHIBIT A </strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>to Cana Pharmaceutical Pledge Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0cm; text-align:center;"><strong><u>Description of Pledged Shares</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Pledgor</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Class</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Stock Certificate No.</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Percentage and Number of Stock </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Held by Pledgor</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Cana Laboratories Holding (Cyprus) Limited</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Common shares</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px; text-align:center;">763.516</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>TOTAL</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">100</td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-10-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EXHIBIT B </u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u><strong>to Cana Pharmaceutical Share Pledge Agreement</strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Addendum to Pledge Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The undersigned, being the Pledgor pursuant to that certain Cana Pharmaceutical Pledge Agreement dated as of February 28<sup style="vertical-align:super">th</sup>, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<strong>Pledge Agreement</strong>&#8221;) in favor of&nbsp;<strong>Cosmos Health Inc</strong>., a Nevada corporation (&#8220;<strong>Pledgee</strong>&#8221;), by executing this Addendum, hereby acknowledges that Pledgor has acquired and legally and beneficially owns all of the issued and outstanding [shares of capital stock ] described below (the &#8220;<strong>Shares</strong>&#8221;) of&nbsp;<strong>Pharmaceutical Laboratories Cana S.A.</strong>, a corporation organized under the laws of the Republic of Greece (&#8220;<strong>Company</strong>&#8221;).&nbsp;&nbsp;Pledgor hereby agrees and acknowledges that the Shares shall be deemed Pledged Shares pursuant to the Pledge Agreement.&nbsp;&nbsp;Pledgor hereby represents and warrants to Pledgee that (i) all of the Shares of the Company now owned by Pledgor are presently represented by the certificates listed below, which certificates, with undated assignments separate from certificate or stock powers duly executed in blank by Pledgor, are being delivered to Pledgee, simultaneously herewith (or have been previously delivered to Pledgee), and (ii) after giving effect to this addendum, the representations and warranties set forth in&nbsp;<u>Section 3</u>&nbsp;of the Pledge Agreement are true, complete and correct as of the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0cm; text-align:center;"><strong><u>Pledged Shares</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Name of the Pledgor</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Class of Equity Interest</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Certificate No.</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0cm"><strong>Percentage of Shares Held by Pledgor</strong></p></td> <td style="width:1%;"><strong>&nbsp;</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;">&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-11-</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">IN WITNESS WHEREOF, Pledgor has executed this Addendum this _____ day of _______________, 202_.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>&nbsp;</td> <td colspan="2"><strong>Cana Laboratories Holding (Cyprus) Limited</strong></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;">&nbsp;</td> <td style="width:3%;">&nbsp;</td> <td style="width:35%;">&nbsp;</td> <td style="width:12%;">&nbsp;</td></tr> <tr style="height:15px"> <td></td> <td>By:</td> <td style="BORDER-BOTTOM: black 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Title:</td> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">-12-</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cosm-20230228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/06/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cosm="http://cosm.com/20230228" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cosm.com/20230228">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://cosm.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20230228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20230228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20230228_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20230228_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
 <import namespace="http://fasb.org/srt-roles/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" />
 <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
 <import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
 <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
 <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
 <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cosm-20230228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/06/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cosm-20230228_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/06/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20230228.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>cosm-20230228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/06/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20230228.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cosm-20230228_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/06/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20230228.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596846371616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cosmos Health Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001474167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 28,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-54436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0611758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">141 West Jackson Blvd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 4236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">60604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">865-0026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>cosm_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cosm-20230228.xsd" xlink:type="simple"/>
    <context id="From2023-02-28to2023-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-02-28to2023-02-28">0001474167</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-02-28to2023-02-28">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-02-28to2023-02-28">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-28to2023-02-28">2023-02-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-02-28to2023-02-28">Cosmos Health Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-28to2023-02-28">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-02-28to2023-02-28">000-54436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-28to2023-02-28">27-0611758</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-28to2023-02-28">141 West Jackson Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-02-28to2023-02-28">Suite 4236</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-28to2023-02-28">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-28to2023-02-28">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-28to2023-02-28">60604</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-28to2023-02-28">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-28to2023-02-28">865-0026</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-02-28to2023-02-28">Common Stock, $.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-28to2023-02-28">COSM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-28to2023-02-28">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2023-02-28to2023-02-28">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-02-28to2023-02-28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-02-28to2023-02-28">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-02-28to2023-02-28">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-28to2023-02-28">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ])],!"D,MM=^=M^( X".L<"V#Z E=R['RHIK[CEXZ%66Z+=VZ#F;LJNEM$
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "S@&96EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( +.
M9E:JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P
M%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\
M>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6V
MG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*
M0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/
MJ!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#
MK+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPY
MZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " "S@&96)!Z;HJT
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M2P$"% ,4    " "S@&96!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +. 9E;T#"8E[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M +. 9E:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ LX!F5A/-Q1]%!    !$  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M +. 9E:?H!OPL0(  .(,   -              "  8@,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ LX!F5I>*NQS     $P(   L              ( !
M9 \  %]R96QS+RYR96QS4$L! A0#%     @ LX!F5JK$(A8S 0  (@(   \
M             ( !31   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +.
M9E8D'INBK0   /@!   :              "  :T1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +. 9E9ED'F2&0$  ,\#   3
M          "  9(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  -P3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cosm_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cosm_8k.htm">cosm_8k.htm</File>
    <File>cosm-20230228.xsd</File>
    <File>cosm-20230228_cal.xml</File>
    <File>cosm-20230228_def.xml</File>
    <File>cosm-20230228_lab.xml</File>
    <File>cosm-20230228_pre.xml</File>
    <File>cosm_ex101.htm</File>
    <File>cosm_ex102.htm</File>
    <File>cosm_ex103.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cosm_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "cosm-20230228_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cosm-20230228_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cosm_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cosm-20230228_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cosm-20230228_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cosm-20230228.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cosm",
   "nsuri": "http://cosm.com/20230228",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cosm_8k.htm",
      "contextRef": "From2023-02-28to2023-02-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://cosm.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cosm_8k.htm",
      "contextRef": "From2023-02-28to2023-02-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001477932-23-001328-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-23-001328-xbrl.zip
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M.JPQ/V-?BI#Z*2QG8494O24K.DV1/D94U>;'2BIPI2/9D!N0E*$5I_>CS.7
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M-?T\Z%[Z6@\Z5K_F6=ZW[WI%77KA7Q&T_9]CU?[43_3=_@]02P,$%     @
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M]\ICSWY7=MKO70@QI)O2J_VX?0902P,$%     @ LX!F5AYEVZV3 @  1 @
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M$IS$8+]'_/9CH2G\$'H8?5AG@3CQU\="R*9A*5;S4OVT%,\]$.Z,J'#FL1C
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M*0PPP\[3LL<_7S[0$]A">ZJ!I^;GF2D<IY!?;:J1_V YESZ!WHAOT4 J?6I
M,8)_DPP&>V: [JN23D$.G/*$EKVTQPE6#<ZCW^<>O>B;A T? SW$^+X&QEC
M<5PBC3S%Q89F8''G2 $PZK*.II=T7Y'I@K-(LKM[NHZ;IV)>F+,$F#"N)2RS
MGD^[>>"?.']/U'E>G"+]QWH!2SRIA"R]LK6I7LG/R7QTC0(9G<.)4E6ALW*"
M/VNVC52Z_<MNJ<8Z.X7S%]$881,GP$SS\W+GSF[?2YCP=<[NJOT.7_8/=GC6
MR_]5_,\_+5,9'HR@O>'A07]__Y-"8UV]W.\?_,-QF?^Y"<+_.'P]NKN$T4_A
M>&4:]0B%1*)>&6"YZ;4>A:N.Y0#$W4WT2X=C%9&&__V^*97.VOT)N?9E;>CY
M(,BN*.1 O!0@KT#KTZI U=_\7L-O0"2]QL/VWA3H0%-K3WY>5_,41.FV N4.
MK(+]X<O#(S6')G66@45$^M?S4-':VG6#.H*61?ERQ+>^"0:=RG)ESKQX) D:
M_@ILC,B@_(4',_TYF4%7-$Z-LA >@#0%37!7H9+FC!TP*DGFGD\3T(S.\SJ-
MT9BAEPJC2U@D$,1U!K^<U*DLC9[/P;@E=QE\+P/*\HI,'GSFU8#VXFY>IS?@
M^R*L$2V\&(<QKOQ:2\MNF([+NC9IU4N:U02I:^W)NEH8#:JW4\B]^H1+CQ;E
M.#_KUNZIP9$I9LOFH^HRLWJH0YT;)/I2>=J//=F0XDRV\P15<J\&X@F!9T!6
M1!Y=-O.F"I1/]#$;MJ\>;SY#OS);T;U@*="8%NH"/76N$QP(4&R.'13X-UH
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MU?;\,_H3DKAU"'&-&PNP'$X+EV1C>Z,9,KAP1#Z$^=>Y/C$;8Y#'IQMD/^\
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M4?7)>8J+%WSY$K]DK9S,"W*4-BV(C]B]A4B(3N_Y5">C0T8)^ICQQ\<SR%[
MBAU>(]*@CS*3#9J&!ZS#&=8M!3Y>4E]^VJ3'<&1BG C9-EOQB\>N79JO:)E+
MRWAWV60? 2TP[[@6E6DB1K:S'NWIN2SDU6N<L0[<#; 5"^8)3%.6819<(WUU
MGY80:U/==8?\*+3Q)K "[,Z@,)[^C&8SV-X9_!.E.IGQ.AK0*V?C MT );.(
MX(PZ;NF<V-[Q(I&2 /8VQS6?DZ5$>.C2._[+9):DNG#?3YC-!EZ8AF)%W@+L
M()G-P<1"[SSJ_RF,7X^3%'6Y>BXZD\/)T0#O[N8.,[0IDA VR+R(XG%\DH+
M 3V2B'):YN1X$28F1'(SH?=[__^?]/]W9=!L/-RX=_+?,2=_US[WCT;#O?V!
M&FZJH\'[H\$Q4$4?<43'JG_P2GWL'QWU#T;#P;$Z?*V LHX./PZ.[BPG;(@*
MJSS\AC[UE*V0$OV^P/D06H(.7VOJG^NB"&RQ$&'=Y)ZD,(CZ0-$0@1M$T#,A
M?+/05-<,$!8]I!&SOKOPINW-;30 #AD'3@;SKNJS+[5:[(*$@:W))FD2L1X
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M8;F(FNL_B6+ 3DFP<\5*0WMHQ44I;.2R7W+9U@W-S@Z^5+ 5?E*PHFOWJ!=
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MFL",1R*:B:=6CNJ3NP MXZJ+$J1?S=KILXG\-S3JF P]E.==E*#UY&J M!
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MN.3DVAB8"99>R?"<I%C4D9F#3$%4(#!&[Y2TRJN":Q*:X-ZHGI1)G(2%04/
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M59@S*2\ZKPELB7ZXZL-V!UO_."U2[#DNP<:4&.[\S)U&6-6=)XYDO%1NILP
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M7$I+3:>ZW0KD:7JVMI:O%\-TL)[E=+E'1&EZN*QF.2:@"T7YN7Z]Z,.!)2C
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MZ/L"[)L@9 L,MXZ18[R%9Q6]?Z%YCS"?5ITUKE#\?E#SMJ!^@G? ?S0*?C9
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M*._LJ-W6D!]Y/JT#[WSF&O#EH]\C3GTW><X=T@]V-N[EN7_!65Y,\GCQ\O\
M4$L! A0#%     @ LX!F5J90)9B&!   @Q8  !$              ( !
M &-O<VTM,C R,S R,C@N>'-D4$L! A0#%     @ LX!F5H9V\%W: 0  BP,
M !4              ( !M00  &-O<VTM,C R,S R,CA?8V%L+GAM;%!+ 0(4
M Q0    ( +. 9E8>9=NMDP(  $0(   5              "  <(&  !C;W-M
M+3(P,C,P,C(X7V1E9BYX;6Q02P$"% ,4    " "S@&96DDOZG!H&  "C.0
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M;W-M7V5X,3 R+FAT;5!+ 0(4 Q0    ( +. 9E:,8!#BUS(  *DQ 0 .
M          "  <&/  !C;W-M7V5X,3 S+FAT;5!+!08     "0 ) #@"  #$
%P@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
